DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Chlorphen Mal Pseudoeph (Chlorpheniramine Maleate / Pseudoephedrine Hydrochloride) - Summary

 
 



SUMMARY

Chlorphen Mal/Pseudoeph HCl 0.8/9 mg Drops is an antihistaminic and decongestant drop for oral administration.

Chlorphen Mal/Pseudoeph HCl 0.8/9 mg Drops is indicated for symptomatic relief of upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold.

See all Chlorphen Mal Pseudoeph indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Chlorphen Mal Pseudoeph (Chlorpheniramine / Pseudoephedrine)

Medical News Today: Oral allergy syndrome: Foods, symptoms, and treatments
Source: Featured Health News from Medical News Today [2017.03.23]
In this article, learn about the causes of allergic reactions that affect the mouth, lips, tongue, and throat, as well as how to manage the condition.

Oral allergy syndrome: Foods, symptoms, and treatments
Source: Allergy News From Medical News Today [2017.03.23]
In this article, learn about the causes of allergic reactions that affect the mouth, lips, tongue, and throat, as well as how to manage the condition.

Do Results from Peanut Allergy Trials Last Long-Term?
Source: MedPage Today Allergy & Immunology [2017.03.08]
(MedPage Today) -- Kids showed high anaphylaxis rate with at-home challenge

Health Tip: Create an Emergency Plan for Deadly Allergy Reaction
Source: MedicineNet Allergy Specialty [2017.03.08]
Title: Health Tip: Create an Emergency Plan for Deadly Allergy Reaction
Category: Health News
Created: 3/8/2017 12:00:00 AM
Last Editorial Review: 3/8/2017 12:00:00 AM

5 Food Allergy Myths
Source: MedicineNet Allergy Specialty [2017.03.07]
Title: 5 Food Allergy Myths
Category: Doctor's & Expert's views on Symptoms
Created: 4/28/2006 12:00:00 AM
Last Editorial Review: 3/7/2017 12:00:00 AM

more news >>

Clinical Trials Related to Chlorphen Mal Pseudoeph (Chlorpheniramine / Pseudoephedrine)

Study of AHIST in Seasonal Allergic Rhinitis Patients [Withdrawn]
Objectives: A) To gather pharmacodynamic measurements and assess blood levels of the active ingredients in AHIST over the dosage interval period of 12 hours. Hypothesis: Hysteresis curves plotting each active ingredient's blood levels over a 12-hour dosage interval will substantiate S5 Symptom Diary scores (IE: evidentiary therapeutic window data); B) To report subjective scores by subjects rating the efficacy of a single dose AHIST in relieving nasal congestion, rhinorrhea, nasal itching, sneezing, and post-nasal drip over a 12-hour dosage interval. Hypothesis: Greater than 66% of subjects will document clinically significant relief over a 12-hour period from one dose of AHIST; C) Report any side effects or adverse drug reactions and rate the severity of any incidence. Hypothesis: Not more than one patient will have an adverse event significant enough to warrant withdrawal; side effects will be mild with the most frequently reported side effect occurring in less than 10% of patients—drowsiness.

Fed Study of Chlorpheniramine Polistirex and Hydrocodone Polistirex Capsules and Tussionex� Pennkinetic� Extended Release Oral Suspension [Completed]
The objective of this open-label, randomized, two-period, crossover study was to evaluate the oral bioavailability of the Mallinckrodt extended release test capsule formulation of chlorpheniramine polistirex/hydrocodone polistirex compared to an equivalent oral dose of a commercially available extended release oral suspension of chlorpheniramine polistirex/hydrocodone polistirex (Tussionex Pennkinetic® Extended Release Oral Suspension, Celltech Pharmaceuticals, Inc.) in a test group of healthy subjects under fed conditions.

Study Evaluating Chlorpheniramine Maleate Liquid in Children and Adolescents [Completed]

Fasting Study of Chlorpheniramine Polistirex and Hydrocodone Polistirex Capsules and Tussionex� Pennkinetic� Extended Release Oral Suspension [Completed]
The objective of this open-label, randomized, two-period, crossover study was to evaluate the oral bioavailability of the Mallinckrodt extended release test capsule formulation of chlorpheniramine polistirex/hydrocodone polistirex compared to an equivalent oral dose of a commercially available extended release oral suspension of chlorpheniramine polistirex/hydrocodone polistirex (Tussionex® Pennkinetic® Extended Release Oral Suspension, Celltech Pharmaceuticals, Inc.) in a test group of healthy subjects under fasting conditions.

StahistRx Phase 2, Five-arm, Parallel Group, Active vs Active, Double-blind Study [Active, not recruiting]
This active vs active comparative trial will evaluate the safety and efficacy of incremental doses of atropine in combination with pseudoephedrine 120 mg/chlorpheniramine 8 mg in adult patients with a history of seasonal allergic rhinitis. Hypotheses are defined by total nasal symptom scores (TNSS) recorded by subjects in diaries where efficacy will be established by statistical significance where p < 0. 05.

more trials >>


Page last updated: 2017-03-23

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017